Shire acquires NPS Pharmaceuticals for $5.2 Billion

Shire acquires NPS Pharmaceuticals for $5.2 Billion

Shire acquires NPS Pharmaceuticals for $5.2 Billion

Shire, the drug maker from Ireland, agreed to buy NPS Pharmaceuticals for $5.2 Billion.

Flemming Ornskov, CEO of Shire, said acquisition was the second “moving-on point” after AbbVie.

 “This is a statement of our intent to be a strong, thriving independent company,” “It speaks to the company’s ability to generate cash and to execute on strategically relevant deals.” he said in an interview.

This deal came, when NPS had biggest valuation in stock market for last ten years. Shire is paying a high premium for a company with little revenue, Mr. Ornskov said.

 “I am confident that this transaction will accelerate our ambition of creating a world where every person living with a rare disease has a therapy,” said Francois Nader, chief executive of NPS. He added that he believed joining the companies would add value for shareholders and continue to help patients with problems like short bowel syndrome and hypoparathyroidism.

Shire’s advisors are Citigroup and Lazard, while Davis Polk & Wardwell and Slaughter & May as legal advisor. Goldman Sachs and Leerink Partners advised NPS, and Skadden, Arps, Slate, Meagaher & Flom provided legal advice.

Mr. Stakebay says:

This deal came after many big deals in pharmaceutical sector and by the words of CEO isn’t last certainly. Shire buys two new drugs Gattex for shore-bowel syndrome treatment and Natpara for hypoparathyroidism treatment. Shire is really strong in cash generating, so we can to except, this deal isn’t last.


CEO of Shire………………………………FLEMMING OMSKOV…..2013-present….$ 2 100 000 (2013)

President, CEO and Director of NPS….FRANCOIS NADER, MD…2008-present…. $ 3 829 170 (2013)






$  6.022 Billion (2014)

$ 155.592 Million (2013)

Operating income

$ 2.593 Billion (2014)

$ – 1.495 billion (2013)


$2.088 Billion (2014)

$ – 13.5 million (2013)

Total assets

$ 13.632 Billion (2014)

$8.32 billion (2013)

Total Equity

$ 8.662 Billion (2014)

$5.36 billion (2013)


5338 (2014)

5338 (2013)

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>